Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
32 hedge funds and large institutions have $18M invested in Acorda Therapeutics in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 23 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
53% more capital invested
Capital invested by funds: $11.8M → $18M (+$6.23M)
29% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $924K
32% less funds holding
Funds holding: 47 → 32 (-15)
61% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.55M |
| 2 |
CCA
Canyon Capital Advisors
Dallas,
Texas
|
+$1.21M |
| 3 |
Renaissance Technologies
New York
|
+$820K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$425K |
| 5 |
CCM
Chilton Capital Management
Houston,
Texas
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$191K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$121K |
| 3 |
Invesco
Atlanta,
Georgia
|
-$66.8K |
| 4 |
Squarepoint
New York
|
-$42K |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$35K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
First Manhattan
New York
| – | +$369 | +3 | New |
|
ACOR Hedge Fund Activity: Q1 2021 in Review
32 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2021, worth a combined $18M — up 53% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ACOR and 9 opened new positions — a net loss of 14 holders — while 7 trimmed existing stakes and 12 added.
The largest buyer was Point72 Asset Management, adding an estimated $4.55M. The largest seller was Vanguard Group, cutting an estimated $191K.
- 32 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2021, down from 47 in Q4 2020.
- Funds reported $18M of Acorda Therapeutics stock for Q1 2021, up 53% quarter-over-quarter.
- 9 funds opened new Acorda Therapeutics positions in Q1 2021 and 23 closed out, a net change of -14 holders.
- The largest Acorda Therapeutics buyer in Q1 2021 was Point72 Asset Management, an estimated $4.55M added.
- The largest Acorda Therapeutics seller in Q1 2021 was Vanguard Group, an estimated $191K sold.
Based on aggregated 13F filings for Q1 2021.